Peptides: what they are and what evidence exists about safety

Peptides are short chains of amino acids and include some approved medicines as well as many experimental products sold online. Researchers and regulators say much of the publicised benefit for unregulated peptides lacks robust human evidence and that products claiming medicinal effects may face regulatory action.

Peptides are short chains of amino acids that occur naturally in the body and have specific biological roles. Interest in using peptides for weight loss, recovery, anti-ageing and mood has expanded from niche athletic circles to a broader public, partly through influencer promotion. Some peptides are the basis of approved prescription medicines, while many products sold online are experimental and have not gone through standard drug regulatory review. Authorities and researchers have raised concerns about evidence gaps, product quality and legal status. Key facts: - Peptides include natural hormones such as insulin, oxytocin and vasopressin and are also produced when proteins are broken down. - Some approved prescription drugs are synthetic peptides with specific, regulated indications, but many products marketed online are experimental and unregulated. - Popular experimental peptides mentioned in reporting include BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu; most lack robust human trials supporting the claimed benefits. - Reviews and experts note that existing studies for many of these peptides are limited to animal or cell research, with few or no randomized controlled trials in humans for the marketed uses. - The UK Medicines and Healthcare products Regulatory Agency (MHRA) says peptide products making medicinal claims must hold a marketing authorisation and that labeling items "for research purposes only" does not prevent regulatory scrutiny. - Researchers have warned about uncertain dosing, potential impurities or contaminants in some products, possible interactions with other medicines, and theoretical risks in biological pathways implicated in tumours. Summary: Interest in peptides has broadened but the evidence base for many marketed experimental products remains limited, often restricted to preclinical studies. Regulators such as the MHRA say products presented as medicines must be authorised and may be subject to enforcement when claims indicate human use. Undetermined at this time.